Literature DB >> 9044748

[Xanthogranulomatous cholecystitis simulating gallbladder neoplasm: therapeutic implications].

C Balagué1, E M Targarona, G Sugrañes, M J Rey, Y Arce, P Viella, M Trias.   

Abstract

Xanthogranulomatous cholecystitis (XGC) is an infrequent type of chronic cholecystitis whose histologic features, in some cases, show a macroscopic appearance which may lead to suspicion of a gallbladder neoplasm with the consequent contraindication of the laparoscopic approach. The incidence of XGC was reviewed in a prospective series of 514 cholecystectomies performed in the authors' department from January 1991 to January 1996. Fourteen cases (2.7%) of XGC were identified with a male/female ratio of 1/1.8 and a mean age of 71 +/- 9 years. The most frequent form of presentation observed was hepatic cholic (43%). Echography showed cholelithiasis in 13 patients (93%). In 3 cases (21%), clinical and echographic suspicion of neoplasm was established, two being in the gallbladder, thus contraindicating the laparoscopic approach. A third patient underwent surgery for suspicion of a colon neoplasm. Xanthogranulomatous cholecystitis presents a macroscopic appearance which may be interpreted as a gallbladder neoplasm in up to 25% of the cases thus leading to treatment with laparoscopy.

Entities:  

Mesh:

Year:  1996        PMID: 9044748

Source DB:  PubMed          Journal:  Gastroenterol Hepatol        ISSN: 0210-5705            Impact factor:   2.102


  3 in total

1.  Xanthogranulomatous cholecystitis in laparoscopic surgery.

Authors:  Gilberto Guzmán-Valdivia
Journal:  J Gastrointest Surg       Date:  2005-04       Impact factor: 3.452

Review 2.  Xanthogranulomatous cholecystitis: What every radiologist should know.

Authors:  Vaibhav P Singh; S Rajesh; Chhagan Bihari; Saloni N Desai; Sudheer S Pargewar; Ankur Arora
Journal:  World J Radiol       Date:  2016-02-28

3.  Xanthogranulomatous cholecystitis: 15 years' experience.

Authors:  Gilberto Guzmán-Valdivia
Journal:  World J Surg       Date:  2004-02-17       Impact factor: 3.352

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.